Kymera Therapeutics KYMR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's EBITDA?
- Kymera Therapeutics (KYMR) reported EBITDA of -$82.13M in Q1 2026.
- How has Kymera Therapeutics's EBITDA changed year-over-year?
- Kymera Therapeutics's EBITDA decreased by 13.5% year-over-year, from -$72.38M to -$82.13M.
- What is the long-term trend for Kymera Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Kymera Therapeutics's EBITDA has grown at a 36.5% compound annual growth rate (CAGR), from -$98.13M to -$341.09M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.